Preventive effect of urinary trypsin inhibitor on the development of liver fibrosis in mice.
Urinary trypsin inhibitor (UTI) is a serine protease inhibitor produced in the liver that inhibits the production and activation of various cytokines, notably transforming growth factor-β (TGF-β), which are associated with the progression of liver fibrosis. However, the various roles of endogenous UTI in liver fibrosis have not been examined. This study, therefore, examined the long-term effects of UTI deficiency during both steady-state conditions and thioacetamide (TA)-induced liver fibrosis. Furthermore, the effects of continuous exogenous UTI administration were examined. Analyses of liver fibrosis marker, hyaluronic acid (HA), TGF-β concentrations and histological findings at 30 weeks of age showed that homozygous UTI-knockout (KO) mice had higher HA and TGF-β concentrations than did heterozygous UTI-KO mice and wild-type mice, although there was no histological evidence of liver fibrosis in these mice. TA treatment for 20 weeks also resulted in greater HA and TGF-β levels in homozygous mice than in heterozygous and wild-type mice. Furthermore, homozygous mice had more severe liver fibrosis based on histological analyses. HA and TGF-β levels were lower in homozygous UTI-KO mice that were continuously administered UTI versus those given distilled water. These findings indicate that UTI deficiency leads to the production of HA and hepatic TGF-β and that administering exogenous UTI can ameliorate these changes. We conclude that endogenous UTI is produced in the liver to suppress the production and activation of TGF-β and that administering exogenous UTI may be therapeutically beneficial for preventing liver fibrosis.
Division of Gastroenterologic and General Surgery, Department of Surgery, Asahikawa Medical University, Asahikawa, 2-1 Midorigaoka-Higashi, Hokkaido 078-8510, Japan. kono@asahikawa-med.ac.jp
Toru
T
Kono
Yurino
Y
Kashiwade
Toshiyuki
T
Asama
Naoyuki
N
Chisato
Yoshiaki
Y
Ebisawa
Masashi
M
Yoneda
Shinichi
S
Kasai
D000818:Animals; D005260:Female; D006023:Glycoproteins / Q000627:therapeutic use*; D006820:Hyaluronic Acid / Q000378:metabolism; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008103:Liver Cirrhosis / Q000473:pathology / Q000517:prevention & control*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008813:Mice, Inbred ICR; D018345:Mice, Knockout; D016212:Transforming Growth Factor beta / Q000378:metabolism
D006023:Glycoproteins; D016212:Transforming Growth Factor beta; D006820:Hyaluronic Acid; C028665:urinastatin